Chandani.B.Patil,
Jagruti.G.Khairnar,
Sunila.A.Patil,
Sunil.P.Pawar,
- Student, B. Pharm, Department of Pharmaceutics, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
- Associate Professor, Department of Pharmaceutical Chemistry, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
- Associate Professor, Department of Pharmaceutical Chemistry, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
- Principal, Department of Pharmaceutical Chemistry, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
Abstract
A complicated, multidisciplinary, and resource-intensive process, the discovery and development of new pharmacological drugs is essential to the advancement of contemporary medicine. Finding and optimising lead chemicals comes after a disease-relevant biological target has been identified and validated. Through preclinical research in animal models, these leads are thoroughly assessed for toxicity, pharmacokinetics, safety, and efficacy. Clinical trials, which are carried out in several stages to evaluate safety, efficacy, ideal dosage, and long-term effects in human populations, are the next step for successful candidates after regulatory assessment.The entire process, from basic research to market approval, typically takes 12 to 15 years and costs between $900 million and $2 billion for each successful treatment since so many compounds fail at different stages.This demonstrates the high level of risk and expense. Allosteric modulation, drug repurposing, multi-target agents, and the combination of biologics and natural products are some of the new drug development techniques that are expanding therapeutic alternatives and efficacy. Improvements in network pharmacology and collaborative research are also helping to identify new drug candidates. Ultimately, developing and discovering new drugs requires scientific ingenuity, effective project management, and perseverance backed by a commitment to moral and legal values.
Keywords: Target Identification, drug development, and drug discovery, Approaches, Pharmaceutics.
Chandani.B.Patil, Jagruti.G.Khairnar, Sunila.A.Patil, Sunil.P.Pawar. Pathways in Drug Discovery and Development: From Molecular Targets to Market Approval. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 13(01):-.
Chandani.B.Patil, Jagruti.G.Khairnar, Sunila.A.Patil, Sunil.P.Pawar. Pathways in Drug Discovery and Development: From Molecular Targets to Market Approval. Research & Reviews: A Journal of Drug Design & Discovery. 2025; 13(01):-. Available from: https://journals.stmjournals.com/rrjoddd/article=2025/view=232357
References
1. Shayne CG. Introduction: Drug Discovery in the 21stCentury. Drug Discovery Handbook, Wiley Press, 2005; 1-10.
2. Smith GC, OíDonnel JT. The Process of New Drug Discovery and Development, Eds., 2nd edition, Informa Healthcare, New York 2006.
3. Moffat J, Vincent F, Lee J, Eder J, Prunotto M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nature Reviews Drug Discovery, 2017; 16(8):531-543.
4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of Health Economics, 2003; 151-185.
5. Lindsay MA. Target discovery. Nature Reviews Drug Discovery,
2003; 2:831–838.
6. Terstappen G, Schlüpen, C, Raggiaschi R, Gaviraghi G. Target deconvolution strategies in drug discovery. Nature Reviews Drug Discovery, 2007; 6(11):891-903.
7. Peet NP. What constitutes target validation? Targets. 2003; 2:125–127.
8. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nature Reviews Drug Discovery, 2006; 5:821-834.
9. Odilia Osakwe. Social Aspects of Drug Discovery, Development and Commercialization. Chapter 6 Preclinical In Vitro Studies: Development and Applicability. Elsevier. 2016.
10. Patidar AK, Selvam G, Jeyakandan M, Mobiya AK, Bagherwal A, Sanadya G, Mehta R. Lead Discovery and lead optimization: A useful strategy in molecular modification of lead compound in analog design. International journal of drug design and discovery. 2011; 2(2):458-463.
11. Huber W. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound–target interactions. J Mol. Recogn. 2005; 18:273–281.
12. Barile FA. Pri. nciples of Toxicological Testing. CRC Press, USA,2008
13. Vogel HG. Drug Discovery and Evaluation 2nd edition. Springer, USA, 2002.
14. Karara AH, Edeki T, McLeod J, et al. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications. Journal of Clinical Pharmacology, 2010; 50:380
15. Fitzpatrick S. The clinical trial protocol. Buckinghamshire: Institute of Clinical Research; 2005.
16.https://www.advarra.com/blog/phases-of-clinical-research-a-detailed-overview
17. Zhang Hong-Yu. One-compound-multiple-targets strategy to combat Alzheimer’s disease. FEBS Lett 2005;579:5260 4.
18. Azvolinsky A. Repurposing existing drugs for new indications. The Scientist January 1 2017.
19. Grover AK. Use of allosteric targets in the discovery of safer drugs. Med Princ Pract 2013;22:418 26.
20. Robles O, Romo D. Chemo- and site-selective derivatizations of natural products enabling biological studies. Nat Prod Rep March 2014;31(3):318 34.
21. Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthcare September 2004;1(4):24 9.
22. Lessl M, Bryans JS, Richards D, Asadullah K. Crowd sourcing in drug discovery. Nat Rev Drug Discover April 2011;10(4):241 2.
23. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol November 2008;4(11):682 90.
| Volume | 13 |
| 01 | |
| Received | 01/09/2025 |
| Accepted | 04/11/2025 |
| Published | 16/11/2025 |
| Publication Time | 76 Days |
Login
PlumX Metrics